Medical Treatment for Diamond Blackfan Anemia

Status Completed

Clinical Trial Summary

Diamond Blackfan anemia (DBA) is a condition in which the bone marrow is underdeveloped. DBA is considered a congenital disease, meaning patients are born with it. In DBA there is a lack of cells that give rise to red blood cells. The other elements produced in the bone marrow, such as white blood cells and platelets, are normal.

Standard treatments used for this disorder such as steroids and bone marrow transplants are associated with failure, relapse, side-effects, increased morbidity, and even death. Two drugs, antithymocyte globulin (ATG) and cyclosporin have been used to treat DBA, but have only provided occasional responses. No study has ever combined these two drugs for the treatment of DBA.

This study is designed to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of DBA.

Clinical Trial Description

Diamond Blackfan anemia (DBA) is a constitutional pure red cell aplasia of unknown etiology. There is laboratory evidence for an immune mechanism and most patients respond to corticosteroids. However the relapse and failure rate are high, and corticosteroids are associated with many short and long term side effects. Patients who do not respond or who do not tolerate corticosteriods require lifelong red blood cell transfusion and iron chelation therapy. Allogeneic bone marrow transplantation is an option for those with a related histocompatible donor, but this procedure is associated with high mortality and morbidity. Other therapies have been tried without general success. Occasional responses to either ATG or cyclosporine have been reported, but no study has used both ATG and cyclosporine. In other blood/bone marrow disorders of immune etiology these drugs have synergistic effects. We propose a Phase II study to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of Diamond Blackfan anemia. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00001749
Study type	Interventional
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase	Phase 2
Start date	July 1998
Completion date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00484848` - Functional Evaluation of Two Types of Totally Implanted Venous Ports	N/A
Completed	`NCT00507533` - Early Application of CPAP in Hematologic	Phase 4
Completed	`NCT00168090` - Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)	Phase 4
Recruiting	`NCT03920735` - Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
Completed	`NCT03013439` - Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)	Phase 1
Completed	`NCT00994136` - Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters	Phase 4
Completed	`NCT01178177` - Radiologic Features of Invasive Pulmonary Aspergillosis	N/A
Completed	`NCT00111215` - Treatment and Management of Women With Bleeding Disorders	N/A
Completed	`NCT00586521` - BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)	Phase 4
Completed	`NCT00782470` - Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A	N/A
Completed	`NCT00001715` - Evaluation of Patients With Blood Disorders
Completed	`NCT01426295` - Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital	Phase 2
Completed	`NCT01220011` - Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.